SCHEMBL5774816

SCHEMBL5774816

COC(=O)C(=Cc1c(F)cccc1Cl)NC=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
BCHE P06276 1/20 0.42
HPGD P15428 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
ALOX12 P18054 1/20 0.40
ATM Q13315 1/20 0.40
RAB9A P51151 4/20 0.40
NPC1 O15118 2/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 2/20 0.39
MDM4 O15151 1/20 0.39
MAPT P10636 1/20 0.39
MDM2 Q00987 1/20 0.39
MEN1 O00255 1/20 0.39
MAT2A P31153 1/20 0.38
KCNH2 Q12809 1/20 0.38
PBRM1 Q86U86 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5777872 0.71 GAA (0.41) LMNAALDH1A1SMN1; SMN2RAB9AKMT2A
SCHEMBL11778569 0.70 MAPT (0.45) ALDH1A1HPGDKMT2AMAPTMEN1
SCHEMBL14198041 0.69 LMNA (0.51) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL19879607 0.67 LMNA (0.47) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL28639377 0.67 PBRM1 (0.45) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL27789673 0.67 LMNA (0.46) LMNAKDM4EALDH1A1BCHEHPGD
SCHEMBL154430 0.67 ALDH1A1 (0.70) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6935703 0.66 GAA (0.47) LMNAHPGDRAB9AKMT2AMAPT
SCHEMBL2222966 0.66 LMNA (0.52) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6935698 0.66 GAA (0.47) LMNAHPGDRAB9AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224189-B1 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 LILLY CO ELI (US) 2006-01-25 EP disclosed
US-20040077675-A1 Compounds and methods for inhibiting MRP1 BONJOUKLIAN ROSANNE (US) 2004-04-22 US disclosed
US-6670373-B1 Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide ELI LILLY AND COMPANY 2003-12-30 US disclosed
EP-1224189-A2 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-07-24 EP disclosed
WO-2001027116-A2 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077675-A1 Compounds and methods for inhibiting MRP1 ABCC1, ABCB1, ABCB11 LMNA 2127/4885KDM4E 4499/4885ALDH1A1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.